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Transcription factors of the forkhead box, class O (FoxO) family are important regulators of the cellular
stress response and promote the cellular antioxidant defense. On one hand, FoxOs stimulate the tran-
scription of genes coding for antioxidant proteins located in different subcellular compartments, such as
in mitochondria (i.e. superoxide dismutase-2, peroxiredoxins 3 and 5) and peroxisomes (catalase), as
well as for antioxidant proteins found extracellularly in plasma (e.g., selenoprotein P and ceruloplasmin).
On the other hand, reactive oxygen species (ROS) as well as other stressful stimuli that elicit the for-
mation of ROS, may modulate FoxO activity at multiple levels, including posttranslational modiﬁcations
of FoxOs (such as phosphorylation and acetylation), interaction with coregulators, alterations in FoxO
subcellular localization, protein synthesis and stability. Moreover, transcriptional and posttranscriptional
control of the expression of genes coding for FoxOs is sensitive to ROS. Here, we review these aspects of
FoxO biology focusing on redox regulation of FoxO signaling, and with emphasis on the interplay
between ROS and FoxOs under various physiological and pathophysiological conditions. Of particular
interest are the dual role played by FoxOs in cancer development and their key role in whole body
nutrient homeostasis, modulating metabolic adaptations and/or disturbances in response to low vs. high
nutrient intake. Examples discussed here include calorie restriction and starvation as well as adipo-
genesis, obesity and type 2 diabetes.
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“Fork head” was ﬁrst identiﬁed in Drosophila as a potential
transcriptional regulator [1], and demonstrated to harbor a so-
called winged-helix DNA binding domain that was then re-
cognized to be present in other transcriptional regulators, in-
cluding the mammalian hepatocyte-enriched nuclear factor
(HNF)-3A (now FoxA1) [2]. This domain was christened the fork
head domain [2], and later the dozens of proteins with such a
winged helix/fork head domain identiﬁed by then were categor-
ized into different classes of forkhead box (Fox) proteins [3]. Fox
proteins – speciﬁcally, the forkhead box, class O, proteins (FoxO) –
were ﬁrst linked to stress resistance when long-lived mutants of
Caenorhabditis elegans were analyzed with respect to genetic traits
contributing to their longevity. It was found that insulin-like sig-
naling along the cascade orthologous to the mammalian insulin
receptor/phosphoinositide 3′-kinase/Akt (InsR/PI3K/Akt) cascade
was involved in that mutants with impaired signaling along this
cascade had extended life spans [4] (Fig. 1). It was then demon-
strated that the daf-16 gene conferred this life span extension [5]
and that DAF-16 (DAF, dauer formation) is a transcription factor of
the Fox family (speciﬁcally, a FoxO orthologue) essential to this
process [6,7].
Mutants with deﬁcient daf-2, coding for a C. elegans InsR
orthologue [8], were then shown to not only display a long-livedFig. 1. Insulin signaling in mammalian cells and in C. elegans. See text for further details.
protein. DAF-16::GFP accumulates in nuclei upon exposure of worms to an oxidative str
with DAF-16::GFP.phenotype but also a phenotype (“Oxr”) characterized by oxidative
stress resistance: A daf-2-inactive mutant had an enhanced re-
sistance towards redox cycling compounds such as paraquat or
menadione [9]. Like the longevity phenotype, this Oxr phenotype
was prevented by mutations in daf-16, suggesting that transcrip-
tional targets of DAF-16 might be involved in conferring stress
resistance. In fact, the expression of sod-3, the gene for one of the
two manganese-containing superoxide dismutases of C. elegans
(but neither sod-1 nor sod-2, coding for Cu, Zn-dependent SOD and
a second Mn-dependent SOD, respectively [10]), was upregulated
in long-lived daf-2mutants, which was prevented by an additional
daf-16 mutation [9].
These ﬁndings suggested that the expression of genes coding
for antioxidant enzymes such as superoxide dismutases might be
under the control of forkhead-type transcription factors. In fact,
expression of the human Mn-SOD (mitochondrial SOD-2 in hu-
mans) was demonstrated to be transcriptionally controlled by the
human DAF-16 orthologue, the forkhead box transcription factor,
FoxO3a [11]. Despite the fact that it was later demonstrated that
SOD-3 is not essential to the longevity phenotype in daf-2mutants
[12], a link was established between forkhead box transcription
factors and cellular antioxidant defense.
The purpose of this review is to provide an overview on the
role of FoxO transcription factors in the cellular response to (oxi-
dative) stress – including antioxidant defense – and on theRight panel: C. elegans transgenic strain TJ356 stably expresses a DAF-16::GFP fusion
ess (induced by diamide, a thiol oxidizing agent). Speckles (arrow) represent nuclei
Fig. 2. Domain organization of human FoxO proteins. Positions of the most conserved domains and of some functionally characterized sequence motifs in human FoxO
proteins are depicted. The numbers next to the domain or motif indicate its beginning and end within the sequence. Total length (in aa, amino acids) of each FOXO protein is
indicated to the right of its schematic depiction. CR1 and CR3, conserved regions 1 and 3; CR3 represents a conserved C-terminal transactivation domain [326,327]. FH/DBD,
forkhead box/DNA-binding domain [129,309,328]; NLS, nuclear localization signal; NES, nuclear export sequence. The amino acid sequence range of FoxO4 NLS is according
to Obsilova et al. [329]. The corresponding homologous regions are depicted for FoxO1a, FoxO3a, and FoxO6 NLS. Whereas NES regions were deﬁned for FoxO1a, 3a and 4
[330–332], the presence of a NES in FoxO6 is being debated [312,313]. The scheme and numbers depicted are based on the following NCBI RefSeq (National Center for
Biotechnology Information Reference Sequence Database; [333]) entries: FoxO1a – NP_002006.2 (GI:9257222); FoxO3a – NP_001446.1 (GI:4503739); FoxO4 – NP_005929.2
(GI:103472003); FoxO6 – NP_001278210.2 (GI:849540648).
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Four FoxO proteins are present in humans (Fig. 2), FoxO1a,
FoxO3a, FoxO4 and FoxO6 (for an overview on FoxO nomenclature,
see [13]). All are widely expressed in diverse tissues [14] – in-
cluding FoxO6, which has frequently been said to be primarily
found in brain, but has now been shown to be ubiquitously ex-
pressed as well [15]. In terms of a functional classiﬁcation of FoxO
target genes, three major categories are “stress response and an-
tioxidative defense”, “metabolism”, and “cell death and prolifera-
tion” [16].2. FoxO target genes: antioxidant defense
FoxO targets include genes coding for both intra- and extra-
cellular antioxidant proteins interfering with all levels of oxygen
reduction that would otherwise generate diverse ROS and cause
oxidative damage to biomolecules. In humans, these FoxO-regu-
lated antioxidants include Mn-SOD (SOD-2) [11], catalyzing dis-
proportionation (dismutation) of the ﬁrst oxygen reduction pro-
duct, superoxide, to generate oxygen and hydrogen peroxide
(H2O2). Moreover, there are indications of a regulation of cyto-
plasmic Cu,Zn-SOD (SOD-1) in murine erythroblasts by FoxOs,
further supporting a role of these transcription factors in the cel-
lular defense against superoxide [17]. H2O2 is further dismutated
to water and oxygen in a reaction catalyzed by catalase, a perox-
isomal heme peroxidase whose generation was found to beregulated by FoxO3a [18]. Alternatively, H2O2 may be reduced to
water at the expense of reducing equivalents provided by NADPH
via thioredoxin or glutathione (GSH), and the formation of two
enzymes catalyzing this reduction was demonstrated to be regu-
lated by FoxOs (peroxiredoxin-3, Prx3, and Prx5) [19,20] or to be
likely regulated by FoxOs (glutathione peroxidase-1, GPx-1) [17],
respectively. The interesting aspect here is that in addition to
peroxisomal catalase, the mitochondrial Prx3 and Prx5, and the
cytoplasmic GPx-1 appear to establish a FoxO-regulated battery of
enzymes ascertaining that H2O2 may be reduced in multiple cel-
lular compartments in parallel. Moreover, the expression of mi-
tochondrial thioredoxin (Trx2) and mitochondrial thioredoxin re-
ductase (TrxR2) were demonstrated to be regulated by FoxO3a in
bovine aortic endothelial cells [20] and can be anticipated to
contribute to the reduction of mitochondrial Prx3.
In the presence of redox-active metal ions, e.g. Fe2þ or Cuþ ,
H2O2 may be reduced in a Fenton-type reaction to generate the
hydroxyl radical OH, a most aggressive oxidant. Chelating such
metal ions would prevent hydroxyl radical formation and its in-
itiating lipid peroxidation and oxidation of other biomolecules. In
cells, chelation of copper ions is achieved by metallothioneins
(MT), and one cellular iron sink is ferritin. Expression of C. elegans
metallothionein-1 and a resulting resistance of the worms towards
copper stress appears to be supported by DAF-16 [21], and ex-
pression of a ferritin ortholog, ftn-1, is regulated by DAF-16 [22].
Similarly, metallothionein mRNA levels were shown in mamma-
lian cells to be increased upon stimulation of FoxO3a, particularly
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(AMPK) [23]. Interestingly, hepatic expression of the major plasma
copper protein in mammals, ceruloplasmin (Cp), is controlled by
FoxOs [24,25]. Cp harbors several copper ions per molecule and
has antioxidant activity in that it acts as ferroxidase to oxidize
Fe2þ released from cells to Fe3þ . Not only does this prevent Fen-
ton-type reactions but it also allows for transport of iron as Fe3þ
by transferrin [26,27].
Another aspect of FoxO proteins regulating antioxidant net-
works was established when expression of the SEPP1 gene, coding
for the major plasma selenoprotein, selenoprotein P (SelP), was
found to be regulated by FoxO1a [28,29]. SelP has some hydro-
peroxidase activity per se [30,31], protecting LDL against oxidation
[32]. However, its major physiological function is the transport of
selenium from the liver to extrahepatic tissues via blood [33],
providing selenium for the synthesis of cellular antioxidant sele-
noenzymes, such as glutathione peroxidases, including GPx-1 and
GPx-4 [34], or thioredoxin reductases, and thus rendering cells
more resistant against oxidative stress [35,36].
In summary, FoxO transcription factors regulate the expression
of genes coding for intra- and extracellular antioxidant proteins,
with different intracellular compartments as well as the major
required steps in antioxidant defense covered (Fig. 3).
Activity of FoxO transcriptional regulators is modulated at
several levels, including (i) posttranslational modiﬁcations, (ii)
subcellular localization, (iii) interaction with coregulators and (iv)
FOXO gene expression and FoxO formation and stability. Sub-
cellular localization and interaction with coregulators are gov-
erned by posttranslational modiﬁcations (PTM), some of which
will be discussed in the following section.3. Redox regulation of FoxO activity
FoxO PTMs that respond to changes in ROS levels and/orFig. 3. FoxO target genes coding for antioxidant proteins: subcellular localization
and functional signiﬁcance of gene products. See text for further details. Ab-
breviations: CP, ceruloplasmin; GPx, glutathione peroxidase; GSH, glutathione;
GSSG, glutathione disulﬁde; LPO, lipid peroxidation; MT, metallothionein; Prx,
peroxiredoxin; SelP, selenoprotein P; SOD, superoxide dismutase; Trx, thioredoxin;
TrxR, thioredoxin reductase. Inset: color code to indicate subcellular localization of
proteins. (For interpretation of the references to color in this ﬁgure legend, the
reader is referred to the web version of this article.)regulate FoxO antioxidant activity include phosphorylation, acet-
ylation and ubiquitination. These modiﬁcations affect FoxO sub-
cellular localization, activity as a transcriptional regulator, and
stability. More recently, methylation and O-glycosylation were
added to the list of FoxO modiﬁcations. For a compilation of FoxO
posttranslational modiﬁcations and the respective FoxO sites of
modiﬁcation, see [16,37].
3.1. Endogenous and exogenous sources of ROS and their effect on
FoxO phosphorylation
Stimulation of receptor tyrosine kinases (RTK) by their natural
ligands frequently comes with a transient generation of ROS – this
is true for stimulation of the insulin receptor with insulin [38], the
epidermal growth factor (EGF) receptor with EGF [39,40] or the
platelet-derived growth factor (PDGF) receptor with PDGF [41].
NADPH oxidases are the source of these ROS, whose formation
results in modulation of downstream signaling. These signaling
events occur through transient oxidative inhibition of protein
tyrosine phosphatases (PTP) that are associated with the re-
spective RTK. This appears to be required for a signiﬁcant ligand-
induced increase in RTK phosphorylation and therefore a sig-
niﬁcant intracellular signal to be initiated. For example, NOX4
generates H2O2, which was shown to attenuate dephosphorylation
of EGFR [42]. Similarly, insulin-dependent signaling is modulated
by NOX-derived reactive oxygen species. Not only does insulin
stimulation of cells cause the generation of H2O2, but this peroxide
formation is also essential to insulin signaling: by reversible oxi-
dation of a redox-sensitive cysteine residue, H2O2 transiently in-
hibits PTP1B, a PTP that controls insulin receptor tyrosine phos-
phorylation [43–45]. A major H2O2 source in insulin-exposed
adipocytes was then identiﬁed as NOX4, whose activity controls
PTP1B activity and insulin receptor-dependent signaling [46].
NADPH oxidase complexes were originally identiﬁed as mem-
brane-bound ﬂavoenzymes responsible for the generation of su-
peroxide in phagocytes upon stimulation. Five different isoforms
of the catalytic subunit, NOX 1 through 5, have been identiﬁed,
and NADPH oxidases are now known to be present in many non-
phagocytes, to be activated by numerous stimuli, and to be crucial
mediators in cellular signaling processes [47,48].
The exact mode of coupling the insulin receptor to NOX4 for an
acute increase in ROS generation is unclear at present, particularly
considering the current view of NOX4 as largely constitutively
active (in contrast to NOX1 or 2) and regulated mainly at the level
of expression [49]. However, a link between insulin exposure and a
prolonged increase in generation of NOX4-derived ROS was es-
tablished in 3T3-L1 ﬁbroblasts [50]; insulin-induced signaling re-
sults in an enhanced expression of NOX4. Interestingly, insulin-
induced NOX4 expression entailed the enhanced formation of
MAPK-phosphatase-1 (MKP1) in that study, a dual-speciﬁcity
phosphatase regulating MAPK phosphorylation that is also known
as an immediate-early gene expressed under stress [51].
Stimulation of RTK-dependent signaling, including insulin sig-
naling, may result in modulation of cascades that ultimately affect
FoxO transcription factors. Two classical RTK-dependent signaling
cascades result in activation of the Ser/Thr kinases Akt (protein
kinase B) and the extracellular signal-regulated kinases (ERK) -1
and -2. Both are stimulated in cells exposed to various stressful
stimuli, including ROS such as hydrogen peroxide, singlet oxygen
or peroxynitrite [52–56]. Moreover, both modulate FoxO activities
(see below). Further stress-responsive kinases include the other
major mitogen-activated protein kinase (MAPK) family members
in addition to ERK-1/ERK-2, p38MAPK isoforms and c-Jun-N-term-
inal kinases (JNKs). Again, p38MAPK and JNKs are stimulated by ROS
and stimuli acting via the formation of ROS, such as ultraviolet
radiation [57–59], singlet oxygen [60,61], peroxynitrite [55] or
Table 1
Phosphorylation sites in FoxO proteinsa.
Kinasesb Sites phosphorylated Comment
Group [304,305] FoxO1a FoxO3a FoxO4 FoxO6




Interaction with 14-3-3 ↑; FoxO1a/3a/4: inactivation, nuclear exclu-
sion; FoxO6: inactivation
SGK T32, (S253), S315 [314] See Akt
PKA T24, S256, S319 [315] See Akt
CMGC [316] JNK Not deﬁned, but likely phosphorylated
[317]; (in vitro only: S294, S425 [78])
T447, T451 [93]c FoxO3a: inactivation, nuclear exclusion [317]
FoxO4: activation, nuclear accumulation [93]
ERK S246, S284, S295, S326 (analogous to human
S329), S413, S415, S429, S467, S475 (numbers
for murine FoxO1) [66]
S294, S344, S425 [65] FoxO1a: enhanced interaction with other transcription factors sug-
gested [66]
FoxO3a: inactivation, nuclear exclusion, Mdm2-mediated degrada-
tion↑ [65]
p38MAPK S284, S295, S326, S467, S475 (numbers for
murine FoxO1) [66]
S7 [78]; (in vitro only: S12, S294, S344,
S425 [78])
FoxO1a: enhanced interaction with other transcription factors hy-
pothesized (in analogy to ERK) [66]
FoxO3a: nuclear accumulation [78]
CDK1 S249 [318] FoxO1a: Interaction with 14-3-3↓;
activation, nuclear accumulation [318]
CDK2 S249, (S298) [94] FoxO1a: inactivation, nuclear exclusion [94]; S249 phosphorylation
veriﬁed, but no nuclear exclusion in some cells [318].
DYRK1 S329 [98] FoxO1a: inactivation, nuclear exclusion [98]
GSK3 S325 (only in vitro) [319]
NLK S329 (plus up to 7 other Ser-Pro) [320] FoxO1a: inactivation, nuclear exclusion [320]
CK1 [321] CK1 S322, S325 [319] FoxO1a: phospho-S319 (Akt/SGK) generates recognition motif for CK1
to phosphorylate S322; thereafter, S325 is phosphorylated [319]. In-
activation, nuclear exclusion.
CAMK AMPK T179, S399, S413, S555, S588, S626 [23] FoxO3a: activation; no effect on subcellular localization [23]
MK5 S215 (murine FoxO1a; analogous to S218 in
hFoxO1a) [322]
S215 (S253, S551, S555) [323] FoxO1a: activation [322]
FoxO3a: nuclear accumulation and activation [323]
STE MST1 S212 [324] S207 (S213, S229/230, S241) [324]d FoxO3a: interaction with 14-3-3↓; nuclear accumulation and activa-
tion [324]
Other IKKβ S644 [325] FoxO3a: inactivation, nuclear exclusion, degradation↑ [325]
PERK S298, (S301, S303) [244] Not deﬁned, but likely phosphorylated
[244]
FoxO1a: nuclear accumulation and activation [244]
a Numbers refer to human FoxO proteins, unless noted otherwise (e.g., ERK, MK5).
b Abbreviations: AGC – kinase group incorporating, among others, the protein kinase A, protein kinase G, protein kinase C families; AMPK – AMP-activated kinase; CAMK – kinase group incorporating calcium and calmodulin-
regulated kinases and related families; CDK – cyclin-dependent kinase; CK – casein kinase; CMGC – kinase group named after some of its members, such as the CDK, MAPK, GSK3, CDK-like kinase families; DYRK – dual speciﬁcity,
tyrosine phosphorylation-regulated kinase; ERK – extracellular signal-regulated kinase; GSK – glycogen synthase kinase; IKK – inhibitor of κB kinase; JNK – cJun N-terminal kinase; MAPK – mitogen-activated protein kinase; MK5 –
MAPK-activated protein kinase (MAPKAPK) 5; MST – mammalian sterile 20-like; NLK – nemo-like kinase; PERK – protein kinase R-like endoplasmic reticulum kinase; PKA – protein kinase A; SGK – serum/glucocorticoid-regulated
kinase; STE – kinase group incorporating several yeast sterile kinase-like kinases.
c FoxO4 phosphorylation sites: the corresponding positions in the current version of the human FoxO4 sequence are T32, S197, S262, T451, and T455 [NCBI RefSeq accession number NP_005929.2 (GI:103472003)].
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three sites in FoxO1a, 3a and 4, at two in FoxO6), as elicited upon
stimulation of cells with insulin, usually results in FoxO inactiva-
tion and nuclear exclusion, resulting in an attenuation of FoxO-
dependent expression of genes like those coding for glucose
6-phosphatase or phosphoenolpyruvate carboxykinase [63, 64].
Similarly, FoxO phosphorylation by ERK-1/-2 causes modulation of
its activity: ERK-dependent phosphorylation of FoxO3a triggers its
poly-ubiquitination by murine double minute (MDM)-2, followed
by FoxO3a degradation [65]. Moreover, Asada et al. identiﬁed
phosphorylation of (murine) Foxo1a by ERK (and by p38MAPK) as
regulating its transcriptional coregulator activity of Ets-1 tran-
scription factor [66].
Mitochondria are another important endogenous source of
ROS. Mitochondrial dysfunction can be the result of a metabolic
imbalance, such as in the case of hyperglycemia, which is also
linked to glycation of proteins and the formation of advanced
glycation end products (AGEs), and fosters other oxidative pro-
cesses causing elevated ROS formation, including NOX activation
and uncoupling of eNOS [67]. Human aortic endothelial cells held
under hyperglycemic conditions had elevated iNOS levels and
activities, enhancing oxidation of LDL coincubated with the cells;
FoxO1a was identiﬁed as the mediator, being upregulated by hy-
perglycemia, inducing iNOS and causing LDL oxidation [68]. High
levels of H2O2 are also generated in peroxisomal fatty acid oxida-
tion – e.g. by fatty acyl-CoA oxidase, the ﬁrst enzyme of the clas-
sical peroxisomal fatty acid β-oxidation system – and in cyto-
chrome P450-dependent xenobiotic metabolism [69–71].
Certain xenobiotics generate reactive oxygen species in cells by
undergoing redox cycles, i.e. they are reduced by cellular enzymes
at the expense of reducing equivalents such as NADH or NADPH,
followed by reoxidation of the product by physically dissolved
molecular oxygen, generating superoxide and reaction products
thereof [72,73]. Certain quinones are examples of such redox cy-
clers and stimulate RTK signaling [74], in part through the gen-
eration of ROS [75], and can thus be expected to affect FoxO-de-
pendent processes by modulating kinases known to phosphorylate
FoxO proteins.
Doxorubicin is an anthraquinone derivative, DNA intercalating
agent and topoisomerase inhibitor known to generate ROS (al-
though probably not through redox cycling of the quinone moiety)
in cells [76]. It is a known stimulator of ERK activation [77] and
also causes p38 activation as well as p38-dependent FoxO3a
phosphorylation (at Ser7), resulting in its nuclear accumulation
and activation in MCF-7 breast cancer cells [78]. Doxorubicin
treatment also appears to affect Foxo expression as it leads to an
upregulation of Foxo1a and 3a mRNA levels in rat cardiac and
skeletal muscle, but it is not known whether ROS formation is
involved in this effect [79].
Redox-active metal ions can undergo redox cycling as well, and
exposure to copper or iron ions will cause the generation of ROS in
cells. Exposure of human hepatoma cells to copper ions strongly
stimulated PI3K/Akt signaling [80] and FoxO phosphorylation and
inactivation [81], which – despite formation of ROS – was in-
dependent of the generation of reactive oxygen species [82]. This
explains why redox-inert metal ions like Zn2þ and Cd2þ also sti-
mulate PI3K/Akt/FoxO signaling in a similar fashion, albeit less
strongly so [82]. Different from these ions, Ni2þ did not stimulate
a signiﬁcant Akt-dependent FoxO phosphorylation [83]. Cu, Zn and
Cd ions share an afﬁnity for thiols, and a direct interaction with
PTPase-type phosphatases such as PTEN was hypothesized as a
potential mechanism of signaling initiation – which was indeed
demonstrated to be the case for Zn [84].
Exposure of cells to arsenite – another molecule with high af-
ﬁnity towards thiols – results in oxidative damage to biomolecules
[85,86], suggesting the generation of ROS. Exposure of ratpheochromocytoma cells to arsenite led to an induction of apop-
tosis via p38-dependent Foxo3a activation, followed by Foxo-de-
pendent Bim-EL expression [87]. In human cells – HaCaT kerati-
nocytes [88] and HepG2 hepatoma cells [89] – a stimulation of
insulin-like signaling was observed, leading to an Akt-dependent
phosphorylation of FoxOs and the inactivation of FoxO signaling.
Interestingly, even certain ﬂavonoids, commonly categorized as
antioxidants, may generate hydrogen peroxide through autoxida-
tion in cell culture [90,91], which may cause stimulation of the
PI3K/Akt cascade and phosphorylation of FoxO proteins, resulting
in their inactivation and nuclear exclusion [92].
MAPK are proline (Pro)-directed kinases, and FoxO proteins
contain several potential phosphorylation sites, i.e. a Ser or Thr,
followed by a Pro residue. Therefore, it comes as no surprise that
not only ERK, but also p38MAPK and JNK were shown to phos-
phorylate FoxO proteins. For example, (murine) Foxo1a – with 15
potential phosphorylation sites (14 of which are conserved in
human FOXO1a) – is phosphorylated by ERK and p38MAPK, but not
by JNK [66], whereas FoxO4 is phosphorylated by JNK under
conditions of oxidative stress, stimulating FoxO4 nuclear accu-
mulation [93].
Other Pro-directed kinases may be expected to phosphorylate
FoxOs – such as cyclin-dependent kinases (CDKs), glycogen syn-
thase kinase-3 (GSK3) or dual speciﬁcity tyrosine-regulated kinase
(DYRK)-1a. In fact, CDK2 was shown to phosphorylate FoxO1a in
response to DNA damage, inducing its nuclear exclusion and in-
activation [94]. In line with a potential direct interactionwith FoxO
proteins, GSK-3 stimulates FoxO transcriptional activity to result in
enhanced IGF1-receptor formation [95]. Nevertheless, no GSK-3-
dependent FoxO phosphorylation in vivo has yet been reported.
DYRK-1a is a Pro-directed kinase [96,97] that phosphorylates
Ser329 in FoxO1a, which appears to slightly support nuclear ex-
clusion and to moderately affect FoxO activity [98]. The ﬂavonoid,
epigallocatechin gallate (EGCG), while generating H2O2 in cell
culture at high concentrations, is a potent inhibitor of DYRK-1a
[99]. This explains why very low EGCG concentrations under
conditions that do not generate any detectable H2O2 in the ex-
perimental setup stimulate nuclear accumulation of FoxO1a rather
than a H2O2-induced nuclear exclusion [92]. Similar effects were
seen with C. elegans: EGCG induced the nuclear accumulation of
DAF-16 and enhanced expression of SOD-3 [92].
In summary, several kinases phosphorylate FoxO proteins in
response to elevated levels of ROS and upon exposure of cells to
stressful stimuli. Table 1 provides a summary of known FoxO
phosphorylation events. Akt, ERK, p38MAPK and JNK are among the
stress-responsive kinases known to target FoxOs, and to contribute
to the modulation of FoxO activity and subcellular localization:
while Akt usually inactivates FoxOs and causes their nuclear ex-
clusion, JNK may phosphorylate and activate FoxO4, stimulating its
nuclear accumulation (see Fig. 4 for an overview on FoxO phos-
phorylation events and their consequences). However, other PTMs
may ﬁne-tune the consequences of FoxO phosphorylation. Thus,
the following section will focus on FoxO acetylation and ubiqui-
tination in the cellular response to oxidative stimuli.
3.2. ROS control of FoxO activity by lysine modiﬁcation: acetylation
and ubiquitination
The ε-amino group of lysine (Lys, K) residues in proteins can be
modiﬁed post-translationally through acetylation and mono- or
poly-ubiquitination. Calnan and Brunet [16] listed six known
acetylation sites each in human FoxO1a (K245, K248, K262, K274,
K294, K559) and in human FoxO3a (K242, K245, K259, K271, K290,
K569) as well as ﬁve acetylation sites each in human FoxO4 (K186,
K189, K215, K237, K407) and in human FoxO6 (K173, K176, K190,
K202, K229). Another previous compilation speciﬁed FoxO1a
Fig. 4. FoxO phosphorylation and its biological consequences. Schematic representation of FoxO phosphorylation by different kinases and the consequences with respect to
activity and subcellular localization. (A) ERK-catalyzed phosphorylation of FoxOs may cause nuclear exclusion and murine double-minute (Mdm)-2-dependent proteasomal
degradation [65]. Similarly, Akt (B) catalyzed FoxO phosphorylation will cause FoxO inactivation, nuclear exclusion and may trigger FoxO degradation (not shown).
Interestingly, FoxO1a phosphorylation at S319 was shown to prime for a consecutive phosphorylation by casein kinase 1 (CK1), which further enhances nuclear exclusion
[319]. FoxO phosphorylation may also result in nuclear accumulation and activation: (C) ER-stress may cause PERK-dependent FoxO phosphorylation and activation [244].
(D) c-Jun-N-terminal kinase (JNK)-dependent FoxO phosphorylation was described as activating (FoxO4 [93]) or inactivating (FoxO3a; dashed lines [317]). Phosphorylation is
indicated by a black “P” on yellow background and stands for phosphorylations at multiple different sites (e.g. Akt: T24, S256, S319 for human FoxO1a). See Table 1 for further
explanations. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Reversible lysine acetylation is accomplished by the action of
histone acetyltransferases and deacetylases: CBP (CREB-binding
protein), p300 and p300/CBP-associated factor (PCAF) acetylate
FoxOs, using acetyl-CoA as co-substrate, whereas enzymes of the
sirtuin (Sirt, orthologues of silent information regulator) family
catalyze NADþ-dependent deacetylation of FoxOs [101–107]. Most
of the acetylation sites in human FoxO proteins surround a con-
sensus site for Akt-induced serine phosphorylation (S256 in the
case of human FoxO1a) within the nuclear localization signal (NLS)
motif, a region that is highly conserved among the FoxO isoforms
[100] (Fig. 2). This conserved localization of major acetylation sites
in the FoxO proteins implies functional links between their acet-
ylation state and metabolic regulation of reversible phosphoryla-
tion, cytoplasmic/nuclear shuttling and transcriptional activity of
FoxOs, which indeed have been identiﬁed and turned out to be
very complex and in part controversial. Acetylation has been
shown to result in both stimulation and inhibition of the tran-
scriptional activity of FoxOs, depending on the examined FoxO
isoforms and their binding partners such as other transcription
factors and transcriptional co-activators, the FoxO target genes and
the cell types used in the studies [103,104,106,108,109]. The mo-
lecular mechanisms underlying those discrepancies are still notcompletely understood. The enzymes in charge of FoxO acetylation
and deacetylation also alter the acetylation state of histones and of
the FoxO coactivator PGC-1α (peroxisome proliferator-activated
receptor γ-coactivator-1α) [110], which may modify the effect of a
stimulus on FoxO-induced gene transcription.
The histone acetyltransferase (HAT) and transcriptional coac-
tivator p300 was initially identiﬁed as a coactivator of FoxO pro-
teins [111]. Early reports stressed the fact that p300-dependent
acetylation of FoxO proteins resulted in enhanced FoxO tran-
scriptional activity [105,112], and the interaction between the two
proteins facilitated the recruitment of p300 to the promoter re-
gions of target genes, where p300 further enhanced gene tran-
scription by recruiting the basal transcriptional machinery and by
facilitating chromatin remodeling through its intrinsic HAT activity
[113]. It was also proposed that p300-mediated acetylation of
FoxOs increase their transcriptional activity. However, it was soon
noted that, at least in some contexts, p300-induced acetylation
could also suppress their transcriptional activity [114]. This
observation was quickly followed by the identiﬁcation of the his-
tone deacetylase Sirt as a positive regulator of FoxO activity [102].
In addition to acetylation, the above-mentioned lysine residues
in FoxO proteins can also become ubiquitinated. Mono-ubiquiti-
nation has been shown to result in nuclear translocation and
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sine residues are shared for acetylation and ubiquitination, dea-
cetylation may facilitate FoxO ubiquitination: deacetylation by
Sirt1 or Sirt2 promoted FoxO3a poly-ubiquitination mediated by
increased binding of the E3 ubiquitin ligase subunit Skp2 and
subsequent FoxO3a proteasomal degradation [116]. As mentioned
above for FoxO3a [65], the phosphorylation state of FoxOs may
also affect their susceptibility to poly-ubiquitination and de-
gradation: FoxO1a has been shown to be ubiquitinated by Skp2,
and prior Akt-mediated phosphorylation at serine residue S256
facilitated FoxO1a poly-ubiquitination [117].
Oxidative stress mediated by increases in intracellular levels
of ROS, speciﬁcally H2O2, has been identiﬁed as a key mediator of
the acetylation and ubiquitination state of FoxOs [101,104,109,
115,118]. Besides H2O2, the redox-cycling oxidant menadione in-
duced transient FoxO3a acetylation, whereas UV and γ-irradiation
had no effect [101]. Importantly, though, application of moderately
high doses of exogenous H2O2, typically 25–500 mM, was required
to trigger interaction of acetyl transferases with FoxOs [101,109].
These doses are considerably higher than the (physiological) levels
of 0.1–7 mM H2O2 that stimulate cellular proliferation and mimic
insulin-induced phosphorylation of FoxOs [119]. In contrast, ap-
plication of exogenous H2O2 in higher micromolar concentrations
initially induces growth arrest and possibly a subsequent cellular
adaptation to oxidative stress [119]. The molecular mechanism of
H2O2-mediated FoxO acetylation has been elucidated for FoxO4:
Exogenously added H2O2 at a minimum concentration of 25 mM
triggered the formation of heterodimers between p300/CBP acet-
ylases and FoxO4 through intermolecular disulﬁde bridges, linking
redox-sensitive cysteine residues [109]. Moreover, an increase in
endogenous cellular ROS production resulting from glucose de-
privation of the culture medium was also sufﬁcient to induce
hetero-dimerization of p300/CBP and FoxO4, whereas the anti-
oxidant N-acetyl cysteine (NAC) counteracted this redox-sensitive
interaction between the proteins [109]. Turnover of the p300/CBP-
FoxO4 complex was regulated by the disulﬁde-reducing activity of
thioredoxin-1 [109], a small antioxidant protein localized both in
cytosol and nucleus [120]. The p300/CBP-FoxO4 interaction is
primarily mediated through cysteine residue C477 in human
FoxO4, and intriguingly, this cysteine residue is conserved among
all human and murine FoxO isoforms [109]. This suggests the
possibility that redox-sensitive hetero-dimerization with acet-
ylases might represent the general mechanism of H2O2-induced
FoxO acetylation. However, a recent screening study identiﬁed
several proteins including peroxiredoxins and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) that bound after H2O2 treat-
ment to the homologous cysteine residue in human FoxO3a
(C622), but acetylases were not included in the provided list. Also,
the other redox-sensitive cysteine residues in human FoxO3a did
not interact with acetyltransferases [121].
Under conditions of oxidative stress, acetylated FoxO3a has
been shown to translocate from the cytosol into the nucleus,
where it may interact with the nuclear sirtuin Sirt1 to become
deacetylated [101]. Sirt1 activity is regulated by the NADþ/NADH
ratio and acts as a sensor of the cellular redox status that becomes
activated when reducing equivalents are limiting [122]. Likewise,
FoxO1a and FoxO4 are deacetylated by Sirt1, causing their nuclear
trapping and modifying their transcriptional activity [102–104]. In
most cases, transcriptional activity of FoxOs is elevated upon
deacetylation. As net result of the successive acetylation and
deacetylation events, deacetylated FoxOs become enriched in the
nucleus and increase transcription of cell cycle arrest genes such
as CDKN1B (coding for cyclin-dependent kinase inhibitor p27Kip1),
DNA repair genes such as GADD45 (growth arrest and DNA da-
mage-inducible protein 45) and genes coding for antioxidant en-
zymes such as SOD-2, whereas transcription of apoptotic genes isdecreased [101, 107, 118]. This switch may allow cells to survive
oxidative and metabolic stresses, as it has been demonstrated for
FoxO3a in the landmark study by Brunet et al. [101]. This model
has since been conﬁrmed for FoxO1a and FoxO4: both successive
acetylation/deacetylation of FoxO1a and FoxO4 induced the ex-
pression of CDKN1B and SOD2 [102,123]. The physiological re-
levance of this regulation was later demonstrated in mouse
models of oxidative stress-induced heart failure [124,125]. The
report by Alcendor et al. [125] also showed that Sirt1-mediated
FoxO deacetylation regulates the catalase gene. A later study de-
monstrated regulation of catalase production by the FoxO/Sirt1
complex in renal tubular cells [126]. Recently, it was found that
Sirt1-mediated FoxO deacetylation regulates FoxO-dependent ex-
pression of genes coding for additional ROS detoxiﬁcation en-
zymes, peroxiredoxins 3 and 5 (Prx3, Prx5), thioredoxin 2 (Trx2),
thioredoxin reductase 2 (TrxR2), and also uncoupling protein 2
(UCP-2), a protein that protects mitochondria from excessive su-
peroxide generation in the electron transport chain (ETC) [20].
Importantly, FoxOs are indispensable for Sirt1-dependent cell
survival under oxidative stress [127]. In another study, successive
acetylation/deacetylation of FoxO1a protected against acute β-cell
failure induced by H2O2, preserving insulin biosynthesis and se-
cretion through induction of the transcription factors NeuroD and
MafA [128]. As deacetylated FoxOs are then again more sensitive
to poly-ubiquitination and proteasomal degradation [116,128], the
(de)acetylation-mediated switch in gene expression of FoxO target
genes is expected to protect cells from acute but not from chronic
stress.
Several studies have analyzed the mechanistic details that
underlie FoxO regulation by successive acetylation/deacetylation.
It has been reported that acetylation by p300 reduces the DNA
binding afﬁnity of FoxO only marginally [129], while it sig-
niﬁcantly destabilizes FoxO binding to nucleosome-bound DNA
[130]. Stable nucleosome binding is essential for efﬁcient FoxO-
dependent chromatin remodeling, because FoxOs work as pioneer
transcription factors capable of binding compacted hypoacetylated
chromatin [131]. Daitoku et al. proposed a model by which for-
mation of the p300–FoxO complex causes histone acetylation and
the recruitment of a preinitiation complex containing RNA poly-
merase II (RNAPII) to the target promoter and the induced tran-
scription could be attenuated by the subsequent FoxO1a acetyla-
tion by CBP [132]. Olmos et al. [20] analyzed Sirt1 binding and
histone acetylation in the promoter regions of Sirt1/FoxO target
antioxidant genes. Their study found that Sirt1 binding to these
promoters was associated with decreased nucleosome acetylation
and decreased RNAPII binding. Importantly, decreased RNAPII
binding was compensated by enhanced formation of elongation
RNAPII complexes, resulting in a net induction of gene expression.
These results may suggest that in those promoters where tran-
scription elongation is not a kinetically limiting factor, Sirt1-de-
pendent lowering of RNAPII binding would lead to transcriptional
down-regulation, while in those where transcriptional elongation
is the kinetically limiting step, Sirt1 activity would result in tran-
scriptional activation. The higher transcriptional activity of dea-
cetylated FoxOs has also been explained by a better binding cap-
ability to target DNA sequences due to the presence of positively
charged lysine residues; conversely, lysine acetylation weakened
the FoxO1a-DNA interaction and made FoxO1a more prone to Akt-
induced S256 phosphorylation and in turn nuclear exclusion [108].
It should be noted, too, that the higher DNA binding capability of
deacetylated FoxOs can result in trans-repression of target genes
of other transcription factors. As an example, iron-induced dea-
cetylation of FoxO1a in adipocytes has been found to decrease
transcription of the PPAR-γ target gene adiponectin due to en-
hanced binding of FoxO1a at the PPAR-γ response element in the
adiponectin promoter [133].
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ulate FoxO activity. It has been shown that the cytosolic isoform
Sirt2 is capable of deacetylating FoxO1a and FoxO3a, thereby
promoting their re-localization from the cytoplasm to the nucleus
and increasing FoxO-dependent transcription of antioxidant en-
zymes [134,135].
Sirt3 is the only sirtuin whose expression has been linked to
human longevity [136,137]. Initially described as a mitochondria-
speciﬁc deacetylase [138], it is in fact a nuclear protein that is
translocated to the mitochondria upon oxidative stress [138,139].
It has been described that FoxO3a and Sirt3 directly interact in the
mitochondria and that Sirt3 activates FoxO3a-dependent gene
expression, probably by increasing the binding of FoxO3a to the
promoters of its target genes [140]. In cardiomyocytes, a Sirt3-
mediated increase in FoxO3a activity prevented cardiac hyper-
trophy through induction of SOD-2 and catalase [141] and by
suppressing the calcium/calcineurin-dependent activation of NFAT
[142]. Therefore, NFAT inhibition might be indirect and mediated
by a reduction in ROS levels.
Also, the role of Sirt6 is increasingly appreciated. In C. elegans, it
has been shown that the Sirt6 orthologue SIR-2.4 promotes nu-
clear localization of the FoxO orthologue DAF-16 in response to
stress [143]. In mammals, studies demonstrating a functional in-
teraction of Sirt6 with FoxO3a relate to cholesterol homeostasis in
the liver. Sirt6 was shown to affect FoxO3a-dependent transcrip-
tion of SREBP2 (sterol-regulatory element binding protein 2), a
major transcriptional regulator of cholesterol biosynthesis, and
PCSK9 (proprotein convertase subtilisin/kexin type 9), a crucial
enzyme for the control of LDL receptor degradation: FoxO3a re-
cruits Sirt6 to the promoters, where Sirt6 histone deacetylation
promotes a repressive chromatin state [144, 145].4. Redox regulation of FOXO expression
Compared to the well-studied regulation of FoxO activity by
posttranslational modiﬁcations and protein-protein interactions,
mechanisms regulating FoxO gene transcription and mRNA stabi-
lity are much less known. Here, we provide examples of studies
that describe up- or downregulation of FoxO gene expression,
often in response to stressful stimuli, including DNA damage, hy-
poxia/reoxygenation, or oxidative stress.
4.1. Transcriptional regulation of FoxO gene expression
The ﬁrst transcription factor identiﬁed as regulating FoxO genes
was E2F-1 [146]. E2F-1 controls cell cycle progression and apop-
tosis in various cell types [147–150]. Nowak et al. [146] found
several putative E2F binding sites in the promoters of the human
FoxO1a and FoxO3a genes. Using a human neuroblastoma cell line
stably expressing an E2F-1-ER (estrogen receptor) fusion protein,
they showed that both FoxO1a and FoxO3a are direct target genes
of E2F-1 and are strongly upregulated by this factor [146]. More-
over, using chromatin immunoprecipitation, the direct binding of
endogenous E2F-1, as well as of E2F-2 and E2F-3, to the FoxO1a
promoter was demonstrated. Of note, upregulation of FoxO by
E2F-1-ER was cell type- and species-speciﬁc [146], pointing to a
possible involvement of additional transcription factors/co-factors
or chromatin modiﬁcations.
A role of the E2F-1/FoxO axis in regulating the apoptotic re-
sponse of cardiomyocytes to ischemia/reperfusion (I/R) injury was
identiﬁed in mice [151,152]. Using E2F-1 knockout mice, Angelis
et al. [151] showed that both E2F-1 and FoxO1a are upregulated in
the wild-type mice after I/R injury, while in E2F-1-null animals
FoxO1a mRNA was not increased. In agreement with that, several
pro-apoptotic FoxO1a target genes were also upregulated in thewild-type but not in the E2F-1 knockout mice, and extent of I/R
injury (infarct area) was attenuated in the mutant animals. The
role of FoxO1a as a critical regulator of cardiomyocyte apoptosis in
response to hypoxia followed by reoxygenation was further con-
ﬁrmed in vitro, using primary adult mouse cardiomyocytes and
neonatal rat ventricular myocytes [151].
In an apparent discrepancy to the above results, Sengupta et al.
[152] showed that FoxO1a and FoxO3a are necessary and sufﬁcient
to promote cardiomyocyte cell survival upon induction of oxida-
tive stress by acute I/R or myocardial infarction (MI). The mice
with conditional, cardiomyocyte-speciﬁc, combined deletion of
FoxO1a and FoxO3a exhibited signiﬁcant increase in infarct area
and decreased expression of anti-apoptotic molecules, antioxidant
enzymes and autophagy-related proteins following I/R, as com-
pared to controls. The same conditional FoxO knockout mice
subjected to MI had increased apoptotic cell death relative to
controls, among other cardiac defects [152]. The seemingly op-
posing results of the two reports could be explained by (i) the dual
role of FoxO in combating oxidative stress – pro-survival and pro-
apoptotic, where both pathways might be activated following the
initial stress signals, and the ﬁnal outcome would depend on the
severity of the cardiomyocyte injury, and (ii) the fact that the
absence of the pro-apoptotic FoxO function in FoxO knockout
cardiomyocytes might be compensated for by some other apop-
totic pathway. Consequently, such cells and cardiac regions would
display a higher degree of injury compared to the wild-type con-
trols, as well as to the imaginary E2F-1 / FoxOþ /þ “control”,
where FoxO pro-apoptotic function could be impaired, while its
pro-survival role would remain operative.
The link between E2F-1 and FoxO may be more intricate than
outlined above. Shats et al. [153] found that FoxO1a and FoxO3a,
with their genes being E2F-1 targets, can act in a feed-forward
regulatory loop by forming a complex with E2F-1 to reinforce gene
induction of multiple apoptotic genes. However, as the experi-
ments were done in U2OS human osteosarcoma cells stably ex-
pressing an E2F-1-ER fusion, it is not clear whether the same type
of regulation can take place also in cardiomyocytes and/or under
conditions of severe hypoxia/reoxygenation. Indeed, at least some
target genes are regulated differently, as the E2F-1/FoxO complex
in U2OS cells upregulates, for example, the classic apoptotic gene
APAF1 [153], whereas APAF1 is not upregulated in the myocardium
after I/R injury [151]. This may reﬂect cell context or species-
speciﬁc (human vs. mouse) differences.
In human ﬁbroblasts, E2F-1 enhances cellular senescence,
whereas FoxOs antagonize senescence by upregulating the for-
mation of ROS scavenging proteins [154,155]. Xie et al. [156]
showed that E2F-1 attenuates FoxO3a-mediated expression of
MnSOD and catalase. They mapped interaction between E2F-1 and
FoxO3a to a region including the DNA binding domain of E2F-1
and the C-terminal transcription activation domain of FoxO3a.
They propose that E2F-1 inhibits FoxO3a function by directly
binding FoxO3a in the nucleus and preventing the activation of its
target genes [156]. Depending on the cellular and promoter con-
text (and possibly also on the redox conditions in the cell), the two
proteins can therefore act synergistically, or one can antagonize
the activity of the other.
The real promoter scenarios are likely to be even more com-
plicated. In their impressive study, Zheng et al. [157] uncovered
the mechanism that underlies and dictates two mutually exclusive
biological outcomes of E2F-1 activity. They describe the site-spe-
ciﬁc methylation of E2F-1 by the asymmetrically dimethylating
protein arginine methyltransferase 1 (PRMT1) and symmetrically
dimethylating PRMT5. Methylation by PRMT1 blocks methylation
by PRMT5, which strengthens E2F-1-driven apoptosis in cells
harboring damaged DNA. Conversely, PRMT5-catalysed methyla-
tion and cyclin A binding to E2F-1 block PRMT1 methylation and
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PRMT1 asymmetric methylation mark on E2F-1 is read on the
promoters of its apoptotic target genes.
E2F-1 is not the only transcription factor known so far to di-
rectly regulate FoxO genes. Two recent reports reveal roles for p53
tumor suppressor protein as an upstream regulator of FoxO3a
[158,159]. Kurinna et al. [158] report FoxO3a as a new p53/p73
target gene. They demonstrate that in the quiescent liver of the
adult mouse, p53 and the transactivating isoform of its homolog
p73 (TA-p73) reside on the FoxO3a promoter and maintain its
transcription active. TA-p73 can bind the same consensus site as
p53, and the authors detected binding of both proteins to a pre-
dicted p53 response element located -3.7 kb upstream of the
FoxO3a transcription start site. In marked contrast to the quiescent
state, transcription of the FoxO3a gene is strongly downregulated
during the proliferative stage of liver regeneration following par-
tial hepatectomy. This is apparently caused by the disruption of
p53, TA-p73, and acetyltransferase p300 binding to, and loss of
active chromatin structure within the FoxO3a promoter region.
The factors maintaining FoxO3a expression are reestablished and
FoxO3a transcription upregulated with the growth completion and
recovery of liver mass [158].
Loss of both p53 function and FoxO3-mediated regulation of
transcription have been linked to increased proliferation and tu-
morigenesis [65,160,161]. In summary, the authors [158] suggest a
regulatory axis between the p53 family members and FoxO tumor
suppressors that functions in the surveillance of normal hepato-
cytes and is temporarily turned off in the course of liver re-
generation. In this context, it would be interesting to survey the
FoxO3a promoter status in various liver cancers.
In the second report, Renault et al. [159] point out a number of
similarities in function between FoxO3a and p53, e.g. in induction
of cell cycle arrest, apoptosis and DNA repair, and to both direct
and indirect interactions between the two proteins (see [159] and
references therein). This raised a question as to whether one of the
proteins could regulate transcription of the other. Indeed, it was
found that p53 speciﬁcally upregulates the transcription of the
mouse FoxO3a gene in embryonic ﬁbroblasts (MEF) and in thy-
mocytes in response to DNA damage [159]. Furthermore, using in
silico searches, the authors found four putative p53 binding sites,
three of them in the promoter and one in the second intron of the
FoxO3a gene. The subsequent chromatin immunoprecipitation
assays with extracts from MEFs identiﬁed p53 binding to the site
in the second intron, but not to those in the promoter region.
Although p53 was bound to the intronic site even in the absence of
DNA damage, its recruitment to the site was slightly increased
following doxorubicin treatment. Moreover, the intronic p53
binding site was proven to be necessary and sufﬁcient for p53-
speciﬁc transactivation of a luciferase reporter. Further experi-
ments showed that FoxO3a is not required for p53-dependent cell
cycle arrest, but it has a role in p53-directed apoptosis [159].
The above two reports describe p53 binding to two sites within
the mouse FoxO3a gene; one located in the promoter region and
the other in the second intron. Notably, the site occupancy by the
p53 protein differs between the adult liver and MEFs, in agree-
ment with different modes of transcriptional regulation in the two
tissues. In quiescent liver, the p53/p73 proteins seem to maintain
FoxO3a expression at a constant level, in order to prevent hepa-
tocyte proliferation, whereas in MEFs the role of p53 is to upre-
gulate FoxO3a following DNA damage. Possibly, different locations
of the binding sites reﬂect involvement of different cooperating
factors/cofactors in order to ensure the proper regulatory mode.
A positive feedback loop in the regulation of FoxO genes tran-
scription has been characterized within the FoxO family itself [162].
Essaghir et al. [162] showed in human ﬁbroblasts that FoxO3a can
upregulate FoxO1a and FoxO4 genes expression. At least with theFoxO1a gene, this is achieved by direct binding of FoxO3a to the
FoxO binding site, identiﬁed in the FoxO1a promoter and char-
acterized in this study. Conversely, all three genes are repressed by
growth factors, e.g. PDGF and FGF, and in case of FoxO1a and FoxO4
this may be achieved by inactivation of FoxO3a protein by phos-
phorylation. Understanding the downregulation of the FoxO3a gene
itself by growth factors such as FGF requires further studies. The
authors conclude that this new mechanism operating at the tran-
scriptional level modulates ﬁbroblast proliferation [162].
By contrast, Zhu et al. [163] report that FoxO3a negatively reg-
ulates autophagy by inhibiting FoxO1a transcription in prostate can-
cer PC3 cells. It is possible that the transactivating effect of FoxO3a on
the FoxO1a promoter is reversed to a repressive one in the tumor cell
line context, however, this issue requires further experiments.
Bakker et al. [164] showed that FoxO3a transcription is upre-
gulated during hypoxia in a hypoxia-inducible factor-1α (HIF-1α)-
dependent manner in MEFs and NIH3T3 ﬁbroblasts. Under these
conditions, FoxO3a in turn induces transcription of CITED2, which
inhibits HIF-1α-induced apoptosis in a negative feedback loop. Thus,
FoxO3a plays a pro-survival role in response to hypoxic stress [164].
The authors found nine HIF-responsive elements conserved in hu-
man and mouse FoxO3a promoters. Whether FoxO3a is a direct
target of HIF-1α has yet to be documented. HIF-1α -dependent in-
crease of FoxO3a mRNA and protein levels under hypoxic conditions
or following hypoxia-mimetic dimethyloxalyl glycine treatment has
more recently been conﬁrmed by Samarin et al. for mouse glo-
merular microvascular endothelial cell line glEND.2 [165].
Two recent reports analyze regulation of FoxO transcription
during fasting and metabolic stress. Wondisford et al. [166] report
increases of FoxO1a transcript and protein levels both in the liver of
mice fasted for 16 h, as well as in hepatocytes treated with dibutyryl
cAMP. The authors identiﬁed and functionally characterized tandem
cAMP-response elements in the FoxO1a promoter and showed that
co-activator p300 regulates FoxO1a gene expression in complex
with the cAMP-response element-binding protein (CREB). Lützner
et al. [167] identiﬁed two functional glucocorticoid-responsive
elements (GREs) in the promoter of the FoxO3a gene. FoxO3 tran-
scription was induced by glucocorticoid receptor (GR)-binding
steroids and further augmented by activation of AMP-activated
protein kinase (AMPK). Moreover, FoxO3a protein upregulated its
own promoter, thus acting in a positive autoregulatory feedback
loop. The study shows how, under conditions of metabolic stress,
GR and high levels of intracellular AMP cooperate to induce FoxO3
gene transcription and post-translationally activate FoxO3a protein
[167]. Multiple functional GREs were recently detected also in the
murine FoxO1 promoter [168]. These experiments, performed in the
C2C12 myoblasts, suggested an additional mechanism by which GR
stimulates muscle atrophy [168].
Finally, the FoxO1a gene has been shown to be a direct tran-
scriptional target of FoxC1 in cultured human trabecular mesh-
work (TM) cells (cells originating from the eye) and in the zebra-
ﬁsh developing eye [169]. FoxC1 binding to an evolutionarily
conserved element in the FoxO1a promoter was demonstrated
in vivo. Furthermore, siRNA-based downregulation of FoxC1 in-
creased cell death in response to oxidative stress in TM cells
(imposed by H2O2 treatment), and in the developing zebraﬁsh eye,
indicating the role of the FoxC1–FoxO1a axis in cellular home-
ostasis and stress protection [169].
While the above data raise an intriguing possibility that E2F-1,
p53, FoxO3a, Hif1, p300, GR, and FoxC1 interact in regulating the
transcription of FoxO genes, there are further reports describing
the up- or downregulation of FoxO gene expression, e.g. during
differentiation processes and/or as a cellular response to certain
physiological cues, with the regulating transcription factor un-
known. For example, an upregulation of FoxO1a and -3a but not -4
mRNAs as well as FoxO1a protein by oxidative stress was observed
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accumulation and apoptosis [170].
As detailed in a later paragraph, FoxO1a is involved in the reg-
ulation of adipocyte differentiation [171,172]. FoxO levels increase
during the differentiation of preadipocytes to mature adipocytes, and
it has been proposed that FoxO1a-mediated upregulation of anti-
oxidant enzymes may limit the risk of oxidative damage provoked by
the generation of intracellular ROS during adipogenesis [173].
FoxO1a is also upregulated during differentiation of human
endometrial stromal cells into decidual cells (endometrial decid-
ualization), a process induced by cAMP and progesterone signaling
and accompanied by elevated ROS levels and oxidative stress [174–
177]. In parallel to the FoxO1a gene induction in the course of the
differentiation, FoxO3a expression is downregulated. It is thought
that while FoxO1a enhances resistance to oxidative damage during
this process, FoxO3a downregulation prevents induction of apop-
tosis in differentiated, decidualized cells [176].
Expression of FoxO genes has also been shown to change in re-
sponse to nutritional and hormonal factors [178], aging and caloric
restriction [179], and as a result of B cell receptor signaling [180,181].
In conclusion, the transcription of FoxO genes is regulated in
response to a number of physiological cues and pathological stress
stimuli that are frequently associated with increased oxidative
stress. The altered FoxO protein levels impact pro-survival or pro-
apoptotic pathways within the cells.
4.2. Posttranscriptional regulation of FoxO levels
Posttranscriptional regulation of FoxO expression emerges as a
new level of complexity in controlling FoxO functions in both
normal and cancer cells. Four distinct mechanisms have been
identiﬁed so far: (i) the RNA-binding protein, HuR, stabilizes FoxO-
mRNA, (ii) the RNA-binding protein Quaking decreases FoxO
mRNA stability, (iii) the FoxO1a 3′UTR may function as a com-
peting endogenous RNA (ceRNA), and (iv) numerous microRNAs
have been described that target FoxO transcripts.
The RNA binding protein HuR responds to stressful stimuli that
cause its cytosolic accumulation. These stimuli include hydrogen
peroxide [182,183], or conditions that generate ROS – including UV
radiation [182,184], exposure to arsenite [185], or tert-butylhy-
droquinone [186]. All these stimuli activate p38MAPK, which di-
rectly or indirectly (e.g., via MAPK-activated kinase-2, MK2) sti-
mulates phosphorylation of HuR, which in turn mediates stress-
induced cytoplasmic accumulation of HuR and enhances its mRNA
stabilizing activity [187–189].
Additionally, it was proposed that HuR itself could act as a redox
sensor. A cysteine residue in the ﬁrst of the three HuR RNA re-
cognition motifs was identiﬁed as crucial for homodimerization.
Homodimerization is required for full HuR activity, and the authors
of the study suggest that this cysteine may respond to oxidative
stress and affect HuR homodimer formation and activity [190].
Li et al. [191] identiﬁed HuR as interacting with the 3′-un-
translated region (3′UTR) of human FoxO1a mRNA, which leads to
transcript stabilization and positive regulation of FoxO1a expres-
sion. Furthermore, 5-ﬂuorouracil (5-FU) treatment induced Fox-
O1a expression in a HuR-dependent manner, and that enhanced
5-FU-induced apoptosis in breast cancer cells [191].
Conversely, Yu et al. [192] showed negative regulation of FoxO1
mRNA at the posttranscriptional level by the RNA-binding protein
Quaking (QKI). QKI binding to three QKI-response elements
(QREs), found in the FoxO1 3′UTR, destabilizes and downregulates
FoxO1 mRNA in breast cancer cell lines [192].
Yang et al. found that miR-9 binds both FoxO1a and E-cadherin 3′
UTR, indicating a competition for this miRNA between the two
transcripts. The results suggest that FoxO1a 3′UTR can function as a
ceRNA, promoting E-cadherin expression and inhibiting epithelial-to-mesenchymal transition and metastasis of breast cancer cells [193].
Numerous reports show that upregulation of speciﬁc micro-
RNAs leads to downregulation of FoxO1a (e.g., miR-137, miR-223,
miR-370) or FoxO3a (e.g., miR-96, miR-155) transcripts in various
cancer cells, thus promoting their proliferation [194–199].
4.3. FoxO transcriptional coregulators in redox regulation of FoxO
activity
The transcriptional coactivator PGC-1α is an upstream regulator
of carbohydrate and lipid metabolism as well as mitochondrial
biogenesis and function that associates with different transcription
factors to regulate target gene expression; and it has been shown
to regulate FoxO activity in different systems [14]. PGC-1α is a
positive regulator of fasting-induced hepatic gluconeogenesis and
this is mediated through its interaction with FoxO1a [200]. Simi-
larly, the FoxO1a-mediated stimulation of selenoprotein P (SelP)
expression in hepatocytes is enhanced by interaction of PGC-1α
with FoxO1a [29]. PGC-1α has also been shown to interact with
FoxO3a to regulate antioxidant gene expression in endothelial
cells and in the skeletal muscle where PGC-1α overexpression is
sufﬁcient to attenuate muscle atrophy induced by expression of a
constitutively active FoxO transgene [201]. Importantly, the role of
PGC-1α inhibition of FoxO3a to increase muscle resistance to
catabolic wasting does not compromise the capacity of PGC-1α to
reduce oxidative stress in cardiac muscle [202].
In the kidney, high fat diet-induced renal lipotoxicity is asso-
ciated with insulin resistance and dyslipidemia, possibly due to
the downregulation of FoxO3a and PGC-1α and associated with
increased oxidative stress. Administration of TEMPOL, a radical
scavenger [203] that was recently shown to prevent renal injury
by modulating PI3K-Akt-FoxO signaling [204], ameliorated high fat
diet-induced renal damage, probably due to the upregulation of
FoxO3a and PGC-1α which resulted in protection against oxidative
stress and lipoapoptosis [205].
Coordinated upregulation of FoxO and PGC-1α in response to
manganese-induced neurotoxicity has been observed, suggesting a
coordinated regulation of antioxidant gene expression [206]. Such a
co-regulation of genes involved in the protection against oxidative
stress has been previously described in endothelial cells [207].
The transcriptional cofactor and lysine demethylase KDM has
recently been shown to induce the expression of genes involved in
antioxidant defense through its interaction with FoxO. The results
show that the principal role for the complex is to maintain the basal
expression of oxidative stress resistance genes rather than their in-
duction in response to exogenous oxidative stress [208]. The results
further suggest that FoxO access to different chromatin contexts and
nuclear microenvironments may rely on different cofactors.
In human cell lines, Ataxin-3/ATXN3 has been shown to interact
with FoxO4 and to increase FoxO-dependent transcription of the
gene coding for SOD-2. Upon stimulation of oxidative stress, ATXN3
and FoxO4 translocate to the nucleus and coordinately induce the
expression of SOD2. Cell lines from patients with spinocerebellar
ataxia type 3, deﬁcient in ATXN3, when exposed to oxidative stress,
show reduced binding of FoxO4 to the SOD2 promoter, impaired
upregulation of SOD-2, and a signiﬁcantly increased formation of
ROS that correlates with the increase in cytotoxicity [209].5. Physiological and pathophysiological consequences of redox
(dys)regulation of FoxOs: selected examples
5.1. Metabolic adaptation to low nutrient intake
The acetylation state of FoxOs affects FoxO-controlled gene
regulation in metabolic adaptation to fasting, caloric restriction
Fig. 5. Schematic representation of the time course of Sirt2, FoxO1a, SOD-2 for-
mation as well as of intracellular ROS levels during adipocyte differentiation in 3T3-
L1 murine preadipocytes. The transient increase in intracellular ROS levels is shut
down through induction of FoxO1a target genes such as SOD-2. Following a brief
period of Akt-dependent phosphorylation of FoxO1a (p-FoxO1a, referring to FoxO
phosphorylated at Ser253 – the equivalent of human FoxO1a Ser256), it is upre-
gulated during adipogenesis, and it becomes transcriptionally active after the clonal
expansion phase due to its deacetylation through interaction with Sirt2
[106,135,171,222].
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both FoxO1a and PGC-1α in hepatocytes, resulting in increased
transcription of gluconeogenic genes and elevated glucose release
from the liver [104,110]. Nutrient deprivation has been shown to
trigger intracellular formation of H2O2 that serves as signaling
molecule for the induction of autophagy [210]. Autophagy is an
adaptation mechanism to support cellular survival during starva-
tion through delivering cytoplasmic constituents to lysosomes for
degradation and recycling [211]. Protein levels of both FoxO1a and
Sirt1 were elevated in cultured cardiac myocytes after 2 h of glu-
cose deprivation; Sirt1-catalyzed deacetylation of FoxO1a caused
an increase in the autophagic ﬂux through stimulating the ex-
pression of Rab7, a GTP-binding protein that mediates the fusion of
autophagosomes and lysosomes [212]. In vivo, deacetylation of
FoxO1a by Sirt1 has also been shown to be required for induction
of autophagy and for resistance against oxidative stress in the
heart [125,212]. Sirt1 expression became elevated in response to
pressure overload and oxidative stress in the heart of wild-type
mice, while moderate Sirt1 overexpression protected the heart of
transgenic mice against paraquat-induced oxidative stress through
up-regulation of the FoxO-dependent antioxidant enzyme catalase
[125]. Apparently, it depends on the cell type whether autophagy
is stimulated by deacetylated or by acetylated FoxO proteins:
FoxO3a controls fasting-induced autophagy during muscle atrophy
[213]. But in contrast to liver and heart, protein levels of Sirt1 have
been reported to decrease in type II skeletal muscle of starved
mice; transgenic overexpression of Sirt1 resulting in FoxO3a dea-
cetylation prevented the up-regulation of atrophy-related genes in
skeletal muscle during fasting [214]. An unexpected molecular
mechanism of autophagy induction, which does not depend on the
activity of FoxOs as transcription factors, has been delineated for
acetylated FoxO1a located in the cytosol of human cancer cell
lines: in response to oxidative stress or serum starvation, cytosolic
FoxO1a became acetylated following its dissociation from Sirt2.
Acetylated FoxO1a then induced the autophagic process through
interaction with Atg7 (ubiquitin-like modiﬁer-activating enzyme
7), a key regulator in the formation of the autophagosome [215].
Activity of FoxO3a under conditions of nutrient restriction has
also been assessed with respect to metabolism and gene regula-
tion in mitochondria [216]. In myotubes, glucose restriction in-
duces the formation of a FoxO3a/Sirt3 complex that recruited
mitochondrial RNA polymerase at mitochondrial DNA-regulatory
regions (mtDNA-RR) to activate mitochondrial transcription, re-
sulting in increased mitochondrial respiration capacity. The re-
levance of Sirt3 regulation of FoxO3a to control mitochondrial
function is further supported by recent studies showing that, in
response to oxidative stress, Sirt3-mediated deacetylation of Fox-
O3a upregulates a set of nuclear genes involved in mitochondrial
homeostasis including biogenesis, fusion/ﬁssion, mitophagy and
ROS control [217–219]. Accordingly, it has been reported that
chronic dietary restriction increases FoxO3a and FoxO4 levels in
skeletal muscle, and these changes correlate with increased ex-
pression of genes associated with stress resistance, antioxidants,
DNA repair, protein turnover and cell death [220].
5.2. Adipocyte differentiation
Sirt2 is the major sirtuin in adipocytes, and deacetylation of
FoxO1a by Sirt2 has been implicated in the regulation of adipo-
genesis [106]. Adipogenesis takes place in adipose tissue, where
mesenchymal stem cells are ﬁrst committed to preadipocytes,
which subsequently undergo clonal expansion, growth arrest and
terminal differentiation into mature fat-accumulating adipocytes
[221]. Hormonal induction of adipocyte differentiation in vitro is
accompanied by a transient increase in intracellular superoxide
and H2O2, as described for human adipose tissue-derived stemcells [173] as well as for murine 3T3-L1 preadipocytes [222], the
most widely used model cell line for the study of adipogenesis.
H2O2 is thought to serve as signaling molecule to increase the
stimulating action of insulin on adipogenesis and lipogenesis;
exogenous application of H2O2 may both induce and augment
adipocyte differentiation of preadipocytes [173,223]. On the other
hand, excessive ROS generation would be detrimental and is thus
counteracted through staggered induction of antioxidant enzymes
such as isoforms of the glutathione peroxidase and thioredoxin
reductase selenoenzymes and the FoxO target genes SOD-2 and
catalase [173,222,224]. Gene expression and protein synthesis,
intracellular localization and posttranslational modiﬁcations
(phosphorylation, acetylation) of FoxO proteins are tightly and
timely regulated in the course of adipocyte differentiation: Fox-
O1a, FoxO3a and FoxO4 mRNA and protein levels are very low in
preadipocytes and increase during adipogenesis, with FoxO1a
being the major FoxO isoform in mature adipocytes and in adipose
tissue [171,173]. While the levels of FoxO1a begin to rise already in
the early stage of adipogenesis, it does not become tran-
scriptionally active before the end of the clonal expansion phase
[171]. The delay in FoxO1a activation is accomplished through
posttranslational modiﬁcations (phosphorylation at S253 of mur-
ine Foxo1a, and acetylation), resulting in FoxO1a exclusion from
the nucleus during the clonal expansion phase [106,171]. Re-
versible acetylation of FoxO1a during adipogenesis is controlled
through strict regulation of Sirt2 levels: Sirt2 is highly expressed in
preadipocytes, strongly down-regulated immediately after the
initiation of adipocyte differentiation and partly restored after the
clonal expansion phase [106,135]. Both overexpression of Sirt2 and
overexpression of a constitutively active FoxO1a mutant, which
cannot be excluded from the nucleus, suppressed adipocyte dif-
ferentiation of preadipocytes [106,135,171]. Conceivably, a strict
control of FoxO expression and activity is crucial for the regulation
of the intracellular redox state during adipogenesis; switching off
FoxOs in early stages ensures more oxidized conditions that favor
adipocyte differentiation, while switching on FoxOs in later stages
counter-acts oxidative damage through induction of FoxO-de-
pendent antioxidant enzymes (Fig. 5).
Fig. 6. Hyperactivation of FoxO1a induced by hyperglycemia and ER stress in the
diabetic liver results in permanent upregulation of FoxO1a target genes. Elevated
hepatic glucose and selenoprotein P (SelP) release may further augment insulin
resistance in type 2 diabetes mellitus. G6Pase, glucose 6-phosphatase; OGT,
O-linked N-acetylglucosamine transferase; PEPCK, phosphoenolpyruvate carbox-
ykinase; PERK – protein kinase R-like endoplasmic reticulum kinase.
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Carbohydrate and lipid homeostasis is not controlled properly
in patients suffering from diabetes mellitus. The metabolic dis-
turbances in diabetes are either caused by lack of insulin due to
autoimmune destruction of pancreatic β-cells (type 1 diabetes
mellitus, T1DM) or by insulin resistance combined with pro-
gressive β-cell failure (type 2 diabetes mellitus, T2DM). Over-
weight and obesity increase the risk to develop T2DM. By 2030,
573 million adults world-wide are projected to be obese and 366
million individuals may have diabetes [225,226]. The steadily in-
creasing prevalence of overweight, obesity and T2DM gave rise to
the concept of a global epidemic of diabetes and to considerable
scientiﬁc efforts to decipher molecular mechanisms underlying
the pathogenesis of T2DM. Oxidative stress is considered a key
factor in the development and progression of diabetes and its
complications. Excess of glucose and saturated fatty acids elicits
overproduction of superoxide and H2O2 through activation of NOX,
elevated oxidative phosphorylation in the mitochondrial re-
spiratory chain and uncoupled NO synthase (NOS) [227]. Other
potentially harmful ROS in obesity and T2DM derive from ER stress
and from chronic low-grade inﬂammation [228]. Oxidative stress
is linked to insulin resistance of liver, skeletal muscle and adipose
tissue [227,228]. The insulin-producing pancreatic β-cells are
particularly susceptible to oxidative stress-induced damage due to
their low expression of antioxidant enzymes [229]. In addition, the
vascular endothelium is impaired in diabetes, because excessive
superoxide lowers the bioavailability of nitric oxide (NO) through
formation of peroxynitrite. This may result in endothelial dys-
function, a major diabetic complication [230]. Increased ﬂux of
glucose and sorbitol through the polyol pathway may contribute to
cellular redox imbalance under hyperglycemic conditions and is
also thought to be involved in the pathogenesis of diabetic com-
plications such as retinopathy, neuropathy, nephropathy and car-
diovascular disease [227].
FoxO proteins, in particular FoxO1, are highly expressed in the
major insulin target tissues as well as in the insulin-producing β-
cells. Hyper-activation of FoxOs has been reported to be associated
with hallmarks of overt diabetes such as hyperglycemia, hyper-
triglyceridemia, insulin resistance and an impaired compensatory
increase in β-cell mass as well as with diabetic complications [231–
234]. Overexpression of constitutively active Foxo1a in liver and
pancreatic β-cells was sufﬁcient to induce diabetes in transgenic
mice, due to increased hepatic glucose production combined with
decreased β-cell compensation [231]. Conversely, haploinsufﬁciency
of the Foxo1 gene rescued the diabetic phenotype of insulin-re-
sistant mice through lowering hepatic expression of gluconeogenic
enzymes and increasing adipocyte expression of insulin-sensitizing
genes [231]. In other studies with transgenic mice, both over-
expression of constitutively active Foxo1a as well as knockdown of
Foxo1a and Foxo3a likewise resulted in hypertriglyceridemia
[232,235]. Diabetic complications such as retinopathy and impaired
fracture healing have been linked to elevated FoxO1a transcrip-
tional activity under hyperglycemic conditions [234,236,237].
However, FoxOs also have beneﬁcial effects with respect to diabetes,
as FoxO-dependent transcription of antioxidant enzymes may
counteract oxidative stress-induced cellular damage [233]. FoxO1-
mediated induction of NeuroD and MafA has been shown to protect
pancreatic β-cells against glucose toxicity [128]. Mice with a triple
knockdown of Foxos (Foxo1a, Foxo3a and Foxo4) in pancreatic β-
cells developed a maturity-onset diabetes of the young (MODY)-like
phenotype characterized by an insulin secretory defect due to im-
paired ATP generation after glucose stimulation and preferential use
of lipids as nutrient source instead of glucose [238].
Dys-regulated hepatic glucose production and release con-
tributes to the fasting and postprandial hyperglycemia that ischaracteristic of overt diabetes. High glucose stimulates tran-
scription of the FoxO target gene glucose-6-phosphatase in the
diabetic liver [239], resulting in a vicious cycle of further increased
hepatic glucose release despite high blood glucose levels in dia-
betes (Fig. 6). Activation of hepatic FoxO1a at high glucose con-
centrations occurs through its coactivator PGC-1α: expression of
PGC-1α is increased in the diabetic liver [240]. In response to high
glucose, PGC-1α binds to the enzyme O-GlcNAc transferase and
targets it to FoxOs, resulting in increased FoxO GlcNAcylation and
increased FoxO-dependent transcription of gluconeogenic en-
zymes [241]. Moreover, hepatic gene expression and secretion of
the FoxO1a target gene SelP is elevated at high glucose con-
centrations [242,243], and this may result in higher plasma SelP
and selenium levels and promote the development of insulin re-
sistance in liver and skeletal muscle [243] (Fig. 6).
FoxO transcriptional activity is also promoted by the protein
kinase PERK (Fig. 4c): PERK has been reported to phosphorylate
FoxOs in response to ER stress, thus overriding the inhibitory effect
of FoxO phosphorylation via the insulin/Akt signaling pathway
[244]. In addition to FoxO activation through posttranslational
modiﬁcations under diabetic conditions, FoxO1a gene expression
has been found to be elevated in the liver of animal models for
T1DM and T2DM [232]. It is still not understood completely how
the actions of FoxOs on hepatic glucose and lipid metabolism are
integrated under conditions of insulin sensitivity and insulin re-
sistance or deﬁciency. A recently published study proposed a
model that distinguishes between early and late stages in the
course of pathogenesis of T2DM [245]: in early insulin resistance,
the reactive increase in β-cell mass and insulin secretion results
initially in hyperinsulinemia and suppression of hepatic FoxO ac-
tivity, thereby switching off gluconeogenesis and redirecting gly-
colysis-derived pyruvate to de novo lipogenesis. In contrast, FoxOs
are strongly activated in overt T2DM, resulting in elevated gluco-
neogenesis, while hepatic lipogenesis is predicted to be stimulated
through the transcription factors sterol regulatory element-bind-
ing protein 1c (SREBP-1c) and carbohydrate-responsive element-
binding protein (ChREBP) [245].
5.4. Cancer
The role of FoxOs in tumor development and progression has
beenwidely investigated. Initially believed to be oncogenes, based on
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tumor development was strongly associated with constitutive acti-
vation of Akt and loss of FoxO activity. It has also been well docu-
mented that loss of FoxO activity is a poor prognosis factor [246–
248]. However, the identiﬁcation of tumor stem cells has further
complicated that picture, since it was recognized that FoxO activity,
even in the presence of constitutively active Akt, was a prevalent
factor linked to drug resistance and invasiveness [234]. FoxOs have a
role in chemotherapy resistance due to their regulation of the
synthesis of enzymes essential for detoxiﬁcation. FoxO1a is involved
in drug resistance in ovarian cancer exposed to paclitaxel, and is
overexpressed in paclitaxel-resistant cancer, attenuating the cyto-
toxic effect [249]. Importantly, controlling the levels of ROS seems to
play a major role in these two aspects of FoxO activity in cancer.
Due to the high degree of homology among FoxO1a, FoxO3a
and FoxO4, there is some functional redundancy, and single or
double FoxO knockout mice frequently do not show clear pheno-
types. Single and double FoxO knockout mice did not show in-
creased rates of tumorigenesis, but the triple deletion of Foxo1a,
Foxo3a and Foxo4 resulted in accelerated tumor progression in
adult mice, together with increased intracellular ROS levels [250].
In contrast, a single knockout of the less related FoxO6 resulted in
increased cellular proliferation and promoted the development of
gastric cancer [251].
Cancer cells tend to have elevated intracellular ROS levels
[252]. ROS can induce cell proliferation and damage DNA, thereby
increasing mutation rates and promoting DNA instability. Elevated
ROS and a low antioxidant capacity render cancer cells generally
more sensitive towards drugs that induce the formation of in-
tracellular ROS, and this sensitivity has been exploited in che-
motherapy [253]. FoxO activity is both crucial to control ROS levels
and promote cell quiescence, and to induce apoptotic cell death in
response to chemotherapeutic drugs.
Inactivation of FoxOs in tumors occurs through several me-
chanisms; many tumors show enhanced activation of the PI3K/Akt
pathway. Inactivation of the phosphatase PTEN is most frequently
observed, resulting in increased FoxO phosphorylation by Akt,
their nuclear exclusion and degradation (see also Fig. 1). Other
growth factor signaling pathways also converge at the inactivation
of FoxO. Importantly, it has been recently described that ROS-de-
pendent oxidation of PTPN12 in breast cancer cells inhibits FoxO
activity by enhancing SGK1-mediated FoxO phosphorylation [254].
As mentioned above, microRNAs modulate FoxO levels. Several
miRNAs have been demonstrated to be involved in the regulation
of FoxO activity in tumor cells. Decreased FoxO levels due to mi-
croRNA-induced downregulation may result in higher prolifera-
tion and tumor growth in gastric cancer [255] and in bladder
cancer [256]. Inactivation of FoxO1a is related to an increase of
microvascular area in cancer via a ROS dependent HIF-1α stabili-
zation and activation of the VEGF pathway [257].
Regarding the role of PTMs, some studies have suggested a role
of p300 acetylation of FoxO factors in inducing apoptotic cell death
in response to a chemotherapeutic agent, particularly those whose
mechanism of action depends on increased cellular oxidative
stress [258].
Cancer cells make limited use of mitochondria for production of
ATP, but they use mitochondria as a source of ROS to stimulate
proliferative signaling and as a source of intermediary metabolites
to fuel cell growth [259]. Importantly, two recent studies have
shown that, in addition to controlling antioxidant gene expression
in cancer cells, FoxO3a inhibits c-Myc through several mechan-
isms: inhibition of c-Myc resulted in downregulation of a large
number of nuclear genes encoding mitochondrial proteins, in
suppression of mitochondrial ROS production and in prevention of
ROS-dependent stabilization of the hypoxia inducible factor HIF-
1α, a key player in tumor development [260]. This pathway islikely to be relevant for normal cellular adaptation to hypoxia,
preventing the excessive production of mitochondrial ROS in re-
sponse to low oxygen tensions [261].6. FoxOs and ROS in different organs
6.1. Liver
The liver as the central metabolic organ has an active meta-
bolism that generates high levels of ROS. In fact, oxidative stress is
implicated in many liver diseases [262–265]. Hepatocytes express
high levels of antioxidant enzymes, but excessive damage or fail-
ure of control mechanisms are common under pathological con-
ditions and generally result in cell death. FoxO3a has recently been
shown to have a pro-apoptotic function in hepatocytes exposed to
excessive oxidative stress. Importantly, knockdown of β-catenin in
hepatocytes rendered mice more sensitive to hepatotoxin-induced
liver injury and resulted in elevated expression of FoxO3a target
genes such as the pro-apoptotic proteins Bim and p27. Conversely,
β-catenin prevented oxidative stress-induced apoptosis through
inhibition of FoxO3a [266]. The Wnt/β-catenin pathway had been
previously implicated in hepatocyte survival and shown to con-
tribute to the activation of cellular antioxidant defense systems,
activating survival pathways and suppressing apoptotic cell death
[267,268]. The functional relevance of this regulatory pathway is
supported by studies carried out in the context of colon cancer
[269–271].
Calorie restriction has been found to result in elevated levels of
FoxO1a and FoxO1a-dependent genes coding for proteins involved
in antioxidant protection, cell cycle arrest, DNA repair and apop-
tosis in the liver; thus, the authors suggested that FoxO1a might
contribute to the anti-neoplastic effect of calorie restriction [272].
The close interplay between metabolic and oxidative control is
highlighted by a recent report that identiﬁed a novel mechanism
of negative regulation of FoxO activity, involving class IIa HDACs
(HDAC4, 5, and 7) in glioblastoma cells. In response to stimulation,
mTORC2 promotes inactivation of class IIa histone deacetylases,
which leads to increased acetylation of FoxO factors, release of
c-Myc inhibition and induction of glycolysis [273]. In contrast, in
response to fasting, glucagon in liver induces the depho-
sphorylation and nuclear translocation of class IIa HDACs, where
they recruit HDAC3, which in turn deacetylates FoxOs and boosts
gluconeogenesis [274].
6.2. Skeletal muscle
The best characterized speciﬁc function of FoxOs in skeletal
muscle is the promotion of muscle atrophy in cachexia and de-
nervation. Studies on the role of acetylation in the control of FoxO
activity in the muscle have evidenced a differential effect of
acetylation on FoxO3a and FoxO1. While increased p300 activity
induces FoxO3a degradation and prevented its nuclear localiza-
tion, it increased FoxO1a nuclear localization [275,276]. Im-
portantly, it has been recently shown that the deacetylation of
FoxO3a by HDAC1 is the main driver of muscle atrophy [277] while
Sirt1-mediated deacetylation of FoxO1a and 3a inhibits muscle
atrophy [214]. In this scenario, it has been an extremely con-
troversial issue whether or not control of ROS levels by FOXOs is
relevant in aging sarcopenia, and if so, which are the relevant
mechanisms involved. A recent study has now conclusively de-
monstrated that FoxOs do not signiﬁcantly contribute to sarcope-
nia in aging [278]. Furthermore, another recent study strongly
argues that FoxO control of ROS in muscle plays a crucial role in
lifespan and healthy aging [279].
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FoxOs have been shown to play an important role in bone
metabolism by inﬂuencing osteoblast generation and survival via
ROS-dependent and -independent mechanisms. FoxO1a inactiva-
tion in osteoblasts decreases osteoblast numbers, bone formation
rate, and bone volume by 50%. Importantly, it has been shown that
FoxO-mediated defense against oxidative stress in osteoblasts
regulates skeletal homeostasis. In fact, the bone formation phe-
notype of FoxO1a osteoblast deﬁcient mice can be attributed to
decreased antioxidant defense mechanisms in the absence of
FoxO1. Elevated ROS activated the p53 signaling cascade, inducing
cell cycle arrest and limiting osteoblast proliferation. The anti-
oxidant N-acetyl cysteine (NAC) normalized redox levels and re-
stored osteoblast proliferation and bone formation [280,281].
Osteoclasts are highly specialized myeloid cells capable of dis-
solving and digesting the organic bone matrix. In vitro, osteoclast
formation induced by parathyroid hormone and interleukin-1 was
accompanied by increased superoxide levels, and superoxide dis-
mutase inhibited osteoclastic resorption, indicating that ROS are
required for osteoclast differentiation and bone resorption [282].
Both RANKL and M-CSF increase the levels of ROS in osteoclast
progenitors and potentiate osteoclast formation and activation
[283,284]. Oxidative stress has been also implicated in the pa-
thologic bone resorption associated with estrogen deﬁciency
[285]. However, the link between ROS generation and osteoclast
formation was circumstantial. A recent study using murine con-
ditional loss or gain of function FoxO mutants, or mitochondria-
targeted catalase in osteoclasts has shown that FoxOs inhibit os-
teoclast differentiation, at least in part, by stimulating catalase
production and thus downregulating H2O2 levels [286].
In cartilage, the expression of FoxO1a and FoxO3a and their
nuclear localization has been found to be reduced both in mice and
humans in the marginal zone of cartilage exposed to maximal
weight – possibly as a consequence of increased levels of pro-in-
ﬂammatory cytokines [287]. A recent study has shown that
knockdown of FoxO1a and FoxO3a in human articular chondrocytes
resulted in signiﬁcantly decreased levels of glutathione peroxidase
1 (GPx-1), catalase, light chain 3 (LC3), beclin1, and Sirt1; following
treatment with tert.-butyl hydroperoxide (tBHP), susceptibility to
ROS-induced apoptotic cell death was increased [288]. This study is
particularly relevant in view of the previously noted observation
that aging chondrocytes show reduced levels of antioxidants and
increased vulnerability to ROS-induced cell death of [289].
6.4. Central nervous system
Brain-speciﬁc ablation of FoxO3a or combined inactivation of
FoxO1a/3a/4 in mice resulted in a phenotype that resembled age-
dependent depletion of the neural stem cell (NSC) population
[290,291]. Furthermore, an ex-vivo assay demonstrated decreased
self-renewal capacity of FoxO knockout cells in an age-dependent
fashion. Decreased self-renewal of FoxO-deﬁcient NSC can be
partially attributable to enhanced intracellular ROS, which leads to
decreased NSC reserve and neurogenesis. Analyses of gene ex-
pression proﬁles showed that FoxO3a regulates genes involved in
cellular quiescence, differentiation, oxygen metabolism and anti-
oxidants [290]. FoxO3a maintains NSC quiescence preventing
premature differentiation under hypoxic conditions by regulating
their entry into the cell cycle and ROS levels [291,292]. These
studies parallel earlier observations on the role of FoxOs in the
control of long-term proliferative capacity of hematopoietic stem
cells [293]. In both studies, administration of the antioxidant NAC
rescued the aberrant proliferation and loss of self-renewal capa-
city, supporting the major role of ROS in FoxO deﬁcient stem cell
phenotypes.The amyloid precursor protein (APP) is a transmembrane pro-
tein that has been involved in the pathogenesis of Alzheimer’s
disease (AD). APP can be cleaved at multiple sites to generate a
series of fragments, including the amyloid β (Aβ) peptides and APP
intracellular domain (AICD). A recent study has shown that FoxO is
a crucial mediator of APP-induced AICD-dependent cell death.
AICD functions as a transcriptional co-activator of FoxO that, to-
gether with FoxO, translocates into the nucleus upon oxidative
stress, and promotes FoxO-induced transcription of the gene en-
coding the pro-apoptotic protein Bim [294].
Astrocytes, in collaborating with neurons in terms of anti-
oxidant defense, contribute to the prevention of oxidative stress-
induced neuronal damage and neurodegeneration [295]. En-
vironmental exposure to manganese and other transition metals
increases cellular oxidative stress and has been associated with an
increased risk of neurodegeneration. A recent report shows that
FoxO levels and activity were induced in astrocytes following Mn
exposure [206].
6.5. Blood
FoxOs have been identiﬁed as mediators of hematopoietic stem
cell resistance to physiologic oxidative stress. Ablation of the three
major FoxO isoforms in hematopoietic stem cells (HSC) results in
excessive proliferation and early exhaustion of the HSC pool, due
to excessive ROS levels in mice [293]. A later study using
hematopoietic progenitors from Drosophila further demonstrated
that ROS control by FoxOs prevents unprimed differentiation.
These results are in line with a number of studies showing that
differentiation factors induce a transient increase in ROS levels in
the target cells [296].
Oxidative stress has also been shown to regulate erythropoi-
esis; in the absence of FoxO3a, excessive ROS levels induce cell
cycle arrest in precursor cells, preventing maturation, and shorten
the viability of mature erythrocyctes [17]. In contrast, myeloid-
speciﬁc triple FoxO knockout mice showed increased proliferation
of granulocyte–monocyte progenitors, resulting in neutrophilia
with monocytosis, increased inducible nitric oxide synthase (iNOS)
expression and oxidative stress in macrophages. As a result, these
mice developed larger atherosclerotic lesions than wild-type
controls, with an increased number of intralesional macrophages,
but a decreased percentage of apoptotic macrophages [297].
Finally, accumulated evidence suggests that downregulation of
Sirt1 and FoxO factors in endothelial cells contributes to oxidative
stress, accelerates senescence [298] and induces apoptosis in re-
sponse to hypoxia [299]. Vascular endothelial senescence has been
proposed as a relevant factor in atherogenesis and diabetic
retinopathy.
6.6. Kidney
Diabetic nephropathy and glycogen storage disease type Ia
(GSD-Ia)-linked nephropathy have been associated with reduced
FoxO activity suppression of antioxidant enzymes and activation of
NADPH oxidases contributing to disease progression [300,301].
6.7. Skin
FoxO1a also functions in keratinocytes to reduce oxidative
stress and prevent cell death as well as to regulate TGF-β signaling.
Importantly, ROS are key mediators of cell migration and TGF-β
signaling. As a result, the role of FoxO in wound healing is dra-
matically different in normal and diabetic mice. FoxO1a plays a
positive role in wound healing in normal mice [302]. It coordinates
the response of keratinocytes to wound healing through upregu-
lation of TGF-β1 and its downstream targets, which are needed for
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oxidative stress is more extreme FoxO1a has been linked to im-
paired wound healing. FoxO1a activity is driven by TNF-α and
associated with higher levels of apoptosis and reduced prolifera-
tion of ﬁbroblasts [303].7. Conclusions
While oxidative stress may contribute to the pathogenesis of
many diseases, low physiological concentrations of ROS, particu-
larly of hydrogen peroxide, have emerged as indispensable sig-
naling molecules in the hormone- and growth factor-mediated
control of cellular metabolism. Apparently, this is not by chance
reminiscent of the partially opposite roles of FoxO transcription
factors in metabolism and stress response under physiological and
pathophysiological conditions. The activity of FoxOs and the cel-
lular redox state are intrinsically linked to each other: FoxOs act as
cellular redox sensors that become modiﬁed post-translationally
through phosphorylation, acetylation and ubiquitination in re-
sponse to oxidative stress, affecting FoxO cytoplasmic/nuclear
shuttling, FoxO stability, and eventually transcription of FoxO-
controlled target genes. Moreover, FoxOs may interact with other
proteins including co-regulators and antioxidant peroxiredoxins in
a redox-sensitive manner, and there is some evidence for redox-
sensitive regulation of FoxO gene expression itself. On the other
hand, some of the FoxO target genes are antioxidant enzymes that
affect the intra- and extracellular redox state by catalyzing dis-
mutation and reduction of superoxide and hydrogen peroxide,
respectively. The net result of FoxO-mediated gene expression
inﬂuences the cell fate upon oxidative damage, inducing either
apoptotic cell death or cell cycle arrest and subsequent repair
processes. Under physiological conditions, FoxOs are involved in
the regulation of cellular differentiation, energy metabolism and
nutrient homeostasis. In contrast, FoxO hyper-activation under
some pathological conditions associated with oxidative stress may
augment metabolic disturbances in type 2 diabetes mellitus or
cause muscle atrophy. Such adverse effects emphasize the need for
a strict and timely control of FoxO expression and activity.Acknowledgments
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